Ocumension details updated board composition and committee assignments

Bulletin Express
06/30

Ocumension Therapeutics outlined the current structure of its Board of Directors and the composition of its three standing committees as of 30 June 2026. The Board comprises eight members: one chairperson, two executive directors, three non-executive directors, and three independent non-executive directors.

• Board leadership – Dr. Lian Yong Chen serves as Chairperson and Non-executive Director. – Executive responsibilities are held by Mr. Ye Liu and Dr. Zhaopeng Hu.

• Non-executive representation – Mr. Yanling Cao and Dr. Qin Xie act as Non-executive Directors.

• Independent oversight – Ms. Beibei Zhuang, Mr. Yiran Huang and Mr. Zhenyu Zhang serve as Independent Non-executive Directors, strengthening governance and regulatory compliance.

• Committee assignments 1. Audit Committee: chaired by Ms. Beibei Zhuang with members Dr. Qin Xie, Mr. Yiran Huang and Mr. Zhenyu Zhang. 2. Remuneration Committee: chaired by Mr. Zhenyu Zhang with members Ms. Beibei Zhuang and Mr. Yiran Huang. 3. Nomination Committee: chaired by Ms. Beibei Zhuang with members Dr. Lian Yong Chen, Mr. Yiran Huang and Mr. Zhenyu Zhang.

The disclosure reaffirms Ocumension’s governance framework by clarifying the oversight responsibilities of its directors and the leadership of each committee.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10